193 related articles for article (PubMed ID: 33887303)
21. Histologic grading of urothelial carcinoma: a reappraisal.
Cheng L; MacLennan GT; Lopez-Beltran A
Hum Pathol; 2012 Dec; 43(12):2097-108. PubMed ID: 22542126
[TBL] [Abstract][Full Text] [Related]
22. Survivin as a useful adjunct marker for the grading of papillary urothelial carcinoma.
Chen YB; Tu JJ; Kao J; Zhou XK; Chen YT
Arch Pathol Lab Med; 2008 Feb; 132(2):224-31. PubMed ID: 18251581
[TBL] [Abstract][Full Text] [Related]
23. Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations.
Williamson SR; Wang M; Montironi R; Eble JN; Lopez-Beltran A; Zhang S; Fan R; Wang L; Osunkoya AO; Koch MO; Cheng L
Mod Pathol; 2014 Nov; 27(11):1540-8. PubMed ID: 24743222
[TBL] [Abstract][Full Text] [Related]
24. Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder.
Reis LO; Taheri D; Chaux A; Guner G; Mendoza Rodriguez MA; Bivalacqua TJ; Schoenberg MP; Epstein JI; Netto GJ
Hum Pathol; 2016 Jan; 47(1):20-5. PubMed ID: 26520419
[TBL] [Abstract][Full Text] [Related]
25. Inverted urothelial papilloma: is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma?
Cheville JC; Wu K; Sebo TJ; Cheng L; Riehle D; Lohse CM; Shane V
Cancer; 2000 Feb; 88(3):632-6. PubMed ID: 10649258
[TBL] [Abstract][Full Text] [Related]
26. Low Grade Papillary Sinonasal (Schneiderian) Carcinoma: A Series of Five Cases of a Unique Malignant Neoplasm with Comparison to Inverted Papilloma and Conventional Nonkeratinizing Squamous Cell Carcinoma.
Saab-Chalhoub MW; Guo X; Shi Q; Chernock RD; Lewis JS
Head Neck Pathol; 2021 Dec; 15(4):1221-1234. PubMed ID: 34041710
[TBL] [Abstract][Full Text] [Related]
27. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up.
Yin H; Leong AS
Am J Clin Pathol; 2004 May; 121(5):679-87. PubMed ID: 15151208
[TBL] [Abstract][Full Text] [Related]
28. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder.
Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Navone R
Am J Surg Pathol; 2001 Dec; 25(12):1528-33. PubMed ID: 11717543
[TBL] [Abstract][Full Text] [Related]
29. Symplastic leiomyomas of the scrotum: a comparative study to usual leiomyomas and leiomyosarcomas.
Matoso A; Chen S; Plaza JA; Osunkoya AO; Epstein JI
Am J Surg Pathol; 2014 Oct; 38(10):1410-7. PubMed ID: 24832157
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of morphometry in low grade papillary urothelial bladder neoplasms.
Ramos D; Ruiz A; Morell L; Navarro S; Villamón R; Gil-Salom M; Llombart-Bosch A
Anal Quant Cytol Histol; 2004 Oct; 26(5):285-94. PubMed ID: 15560535
[TBL] [Abstract][Full Text] [Related]
31. High-grade papillary urothelial carcinoma of the urinary tract: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center.
Chaux A; Karram S; Miller JS; Fajardo DA; Lee TK; Miyamoto H; Netto GJ
Hum Pathol; 2012 Jan; 43(1):115-20. PubMed ID: 21820145
[TBL] [Abstract][Full Text] [Related]
32. Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system.
Zaleski M; Gogoj A; Walter V; Raman JD; Kaag M; Merrill SB; Drabick J; Joshi M; Holder S; DeGraff DJ; Warrick JI
Hum Pathol; 2019 Feb; 84():275-282. PubMed ID: 30359638
[TBL] [Abstract][Full Text] [Related]
33. Urothelial carcinoma in situ with "overriding" features can evade detection by mimicking umbrella cells.
Bahceci D; Nguyen JK; Sangoi AR; Stohr BA; Chan E
Hum Pathol; 2023 Jun; 136():56-62. PubMed ID: 36997033
[TBL] [Abstract][Full Text] [Related]
34. The Paris System "atypical urothelial cells" category: can the current criteria be improved?
Vosoughi A; Ordobazari A; Lora Gonzalez MA; Guido LP; Skiba M; Campuzano-Zuluaga G; Kryvenko ON; Gomez-Fernandez C; Garcia-Buitrago M; Jorda M
J Am Soc Cytopathol; 2021; 10(1):3-8. PubMed ID: 32732113
[TBL] [Abstract][Full Text] [Related]
35. Morphological predictors for microsatellite instability in urothelial carcinoma.
Sobrino-Reig E; Meizoso T; García J; Varillas-Delgado D; Martin YB
Diagn Pathol; 2021 Nov; 16(1):106. PubMed ID: 34801034
[TBL] [Abstract][Full Text] [Related]
36. Multiparametric Classification of Non-Muscle Invasive Papillary Urothelial Neoplasms: Combining Morphological, Phenotypical, and Molecular Features for Improved Risk Stratification.
Montes-Mojarro IA; Hassas S; Staehle S; Sander P; Harland N; Serna-Higuita LM; Bonzheim I; Bösmüller H; Stenzl A; Fend F
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897708
[TBL] [Abstract][Full Text] [Related]
37. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy.
Holmäng S; Andius P; Hedelin H; Wester K; Busch C; Johansson SL
J Urol; 2001 Apr; 165(4):1124-8; discussion 1128-30. PubMed ID: 11257652
[TBL] [Abstract][Full Text] [Related]
38. Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets.
Musangile FY; Matsuzaki I; Iwamoto R; Sagan K; Nishikawa M; Mikasa Y; Takahashi Y; Kojima F; Hara I; Murata SI
Mod Pathol; 2023 May; 36(5):100120. PubMed ID: 36812689
[TBL] [Abstract][Full Text] [Related]
39. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
[TBL] [Abstract][Full Text] [Related]
40. Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications.
Cheng L; Neumann RM; Bostwick DG
Cancer; 1999 Nov; 86(10):2102-8. PubMed ID: 10570438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
